Investigation and management of the monoclonal gammopathy of undetermined significance A British Society for Haematology Good Practice Paper

This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.

Automated summary

This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of MGUS. It also discusses the entity of MGCS and how it should be managed. Additionally, the potential for targeted population screening for MGUS is explored.